Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad5-nCoV Booster in Children and Adolescents
NCT05169008Phase 3Terminated
- Sponsor
- CanSino Biologics Inc.
- Start
- Feb 2022
- Primary completion
- Jan 2023
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ad5-ncov in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by CanSino Biologics Inc. Primary endpoints: Incidence of Serious Adverse Events at 12 months and Immunogenicity of S-RBD IgG antibody at 28 days. Started Feb 2022; status: terminated.
02
Drugs
ad5-ncov
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05169008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05169008.